Stewart & Patten Co Trimmed Its Qualcomm (QCOM) Position; Anthera Pharmaceuticals (ANTH)’s Sentiment Is 1.13

August 3, 2017 - By Vivian Currie

Anthera Pharmaceuticals, Inc. is a biopharmaceutical firm focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The company has market cap of $12.80 million. The Firm has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod. It currently has negative earnings. Sollpura is a non-porcine investigational Pancreatic Enzyme Replacement Therapy (PERT) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (EPI), often seen in patients with cystic fibrosis and other conditions.

Stewart & Patten Co Llc decreased Qualcomm Inc (QCOM) stake by 6.7% reported in 2016Q4 SEC filing. Stewart & Patten Co Llc sold 14,615 shares as Qualcomm Inc (QCOM)’s stock rose 2.14%. The Stewart & Patten Co Llc holds 203,566 shares with $13.27M value, down from 218,181 last quarter. Qualcomm Inc now has $77.99B valuation. The stock declined 0.63% or $0.33 reaching $52.83 per share. About 4.16M shares traded. QUALCOMM, Inc. (NASDAQ:QCOM) has risen 9.31% since August 3, 2016 and is uptrending. It has underperformed by 7.39% the S&P500.

About 61,996 shares traded. Anthera Pharmaceuticals Inc (ANTH) has declined 93.94% since August 3, 2016 and is downtrending. It has underperformed by 110.64% the S&P500.

Ratings analysis reveals 50% of Anthera Pharma’s analysts are positive. Out of 4 Wall Street analysts rating Anthera Pharma, 2 give it “Buy”, 0 “Sell” rating, while 2 recommend “Hold”. The lowest target is $1.35 while the high is $3.0. The stock’s average target of $2.18 is 71.65% above today’s ($1.27) share price. ANTH was included in 4 notes of analysts from December 29, 2016. The company was downgraded on Thursday, December 29 by Citigroup. As per Thursday, December 29, the company rating was maintained by H.C. Wainwright. The stock of Anthera Pharmaceuticals Inc (NASDAQ:ANTH) earned “Overweight” rating by Piper Jaffray on Thursday, December 29. The firm has “Hold” rating given on Thursday, December 29 by Jefferies.

Abingworth Llp holds 0.98% of its portfolio in Anthera Pharmaceuticals Inc for 861,723 shares. Rhenman & Partners Asset Management Ab owns 200,000 shares or 0.02% of their US portfolio. Moreover, Rock Springs Capital Management Lp has 0.02% invested in the company for 380,000 shares. The California-based Bvf Inc Il has invested 0.01% in the stock. White Pine Capital Llc, a Minnesota-based fund reported 35,000 shares.

Analysts await Anthera Pharmaceuticals Inc (NASDAQ:ANTH) to report earnings on August, 8. They expect $-1.08 earnings per share, up 61.43% or $1.72 from last year’s $-2.8 per share. After $-2.03 actual earnings per share reported by Anthera Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts -46.80% EPS growth.

Among 33 analysts covering Qualcomm Inc. (NASDAQ:QCOM), 11 have Buy rating, 1 Sell and 21 Hold. Therefore 33% are positive. Qualcomm Inc. had 95 analyst reports since July 23, 2015 according to SRatingsIntel. The firm has “Buy” rating by Mizuho given on Friday, September 30. The rating was maintained by Cowen & Co with “Outperform” on Thursday, July 23. The firm earned “Buy” rating on Thursday, July 21 by Canaccord Genuity. As per Monday, October 31, the company rating was upgraded by Nomura. The rating was upgraded by Susquehanna on Wednesday, January 13 to “Positive”. BMO Capital Markets downgraded QUALCOMM, Inc. (NASDAQ:QCOM) on Friday, July 15 to “Underperform” rating. Charter Equity downgraded QUALCOMM, Inc. (NASDAQ:QCOM) on Tuesday, January 24 to “Mkt Perform” rating. The company was downgraded on Thursday, November 10 by Morgan Stanley. On Wednesday, December 16 the stock rating was maintained by Topeka Capital Markets with “Hold”. RBC Capital Markets maintained the shares of QCOM in report on Monday, October 3 with “Sector Perform” rating.

Since May 11, 2017, it had 1 insider purchase, and 4 sales for $1.73 million activity. Rosenberg Donald J also sold $588,767 worth of QUALCOMM, Inc. (NASDAQ:QCOM) shares. On Saturday, May 20 the insider STERLING MICHELLE M sold $325,654. ROGERS ALEXANDER H also sold $26,922 worth of QUALCOMM, Inc. (NASDAQ:QCOM) shares. ABERLE DEREK K also sold $1.28 million worth of QUALCOMM, Inc. (NASDAQ:QCOM) on Thursday, June 1. $491,286 worth of QUALCOMM, Inc. (NASDAQ:QCOM) was bought by LIVERMORE ANN M.

Investors sentiment decreased to 1.01 in 2016 Q4. Its down 0.07, from 1.08 in 2016Q3. It dropped, as 104 investors sold QCOM shares while 514 reduced holdings. 139 funds opened positions while 483 raised stakes. 1.12 billion shares or 0.18% less from 1.12 billion shares in 2016Q3 were reported. Clearbridge Llc accumulated 5,628 shares. Moreover, Blume has 4.22% invested in QUALCOMM, Inc. (NASDAQ:QCOM) for 107,802 shares. Hanson & Doremus Inv Mngmt reported 250 shares. Boston Private Wealth Ltd Company, a Massachusetts-based fund reported 69,443 shares. Garrison Bradford And Associate holds 1.08% or 18,024 shares. State Street owns 67.53M shares. Wellington Shields Capital Mngmt Limited Co stated it has 6,180 shares or 0.07% of all its holdings. Water Island Cap Limited Liability Corporation owns 60,000 shares. Hexavest invested in 856,313 shares or 1.07% of the stock. Weaver C Barksdale Associate invested in 14,988 shares or 1.57% of the stock. Cornerstone Advisors holds 0.19% or 16,000 shares. 2.19 million were reported by Hsbc Pcl. Novare Capital Management Limited owns 74,688 shares or 1.2% of their US portfolio. Horizon Kinetics Ltd Liability Corporation holds 0.01% of its portfolio in QUALCOMM, Inc. (NASDAQ:QCOM) for 5,887 shares. Pensionfund Dsm Netherlands holds 93,000 shares or 0.88% of its portfolio.